1
|
He X, Liao J, Liu F, Yan J, Yan J, Shang H, Dou Q, Chang Y, Lin J, Song Y. Functional repair of p53 mutation in colorectal cancer cells using trans-splicing. Oncotarget 2015; 6:2034-45. [PMID: 25576916 PMCID: PMC4385834 DOI: 10.18632/oncotarget.2988] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Accepted: 12/09/2014] [Indexed: 12/20/2022] Open
Abstract
Mutation in the p53 gene is arguably the most frequent type of gene-specific alterations in human cancers. Current p53-based gene therapy contains the administration of wt-p53 or the suppression of mutant p53 expression in p53-defective cancer cells. We hypothesized that trans-splicing could be exploited as a tool for the correction of mutant p53 transcripts in p53-mutated human colorectal cancer (CRC) cells. In this study, the plasmids encoding p53 pre-trans-splicing molecules (PTM) were transfected into human CRC cells carrying p53 mutation. The plasmids carrying p53-PTM repaired mutant p53 transcripts in p53-mutated CRC cells, which resulted in a reduction in mutant p53 transcripts and an induction of wt-p53 simultaneously. Intratumoral administration of adenovirus vectors carrying p53 trans-splicing cassettes suppressed the growth of tumor xenografts. Repair of mutant p53 transcripts by trans-splicing induced cell-cycle arrest and apoptosis in p53-defective colorectal cancer cells in vitro and in vivo. In conclusion, the present study demonstrated for the first time that trans-splicing was exploited as a strategy for the repair of mutant p53 transcripts, which revealed that trans-splicing would be developed as a new therapeutic approach for human colorectal cancers carrying p53 mutation.
Collapse
Affiliation(s)
- Xingxing He
- Institute of Liver Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jiazhi Liao
- Institute of Liver Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Fang Liu
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Junwei Yan
- Institute of Liver Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jingjun Yan
- Institute of Liver Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Haitao Shang
- Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Qian Dou
- Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Ying Chang
- Institute of Liver Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jusheng Lin
- Institute of Liver Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yuhu Song
- Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
2
|
Shen X, Lin JS, Kong XJ. Maxizyme against mtp53 transfected by adenovirus enhanced transferrin receptor-mediated gene delivery systeminduced apoptosis of hepatoma cells. Shijie Huaren Xiaohua Zazhi 2004; 12:1539-1542. [DOI: 10.11569/wcjd.v12.i7.1539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the influence of introduction of maxizyme against mtp53 by adenovirus enhanced transferrin receptor-mediated gene delivery system on MHCC97 cells.
METHODS: Hepatoma cell line MHCC97 containing mutated p53 gene was served as a model. The maxizyme against mtp53 was transfected to the cells by adenovirus enhanced transferrin receptor-mediated gene delivery system. The level of mtp53-mRNA was detected by means of semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). The apoptosis of the hepatoma cells was measured by DNA ladder assay and FCM.
RESULTS: After 48 hours of transfection by AVET system, RT-PCR results indicated the expression of mtp53 mRNA in pEGFP-Maxizyme group was significantly lower than that in control group. And DNA "ladder" with agarose gel electrophoresis was observed in pEGFP-maxizyme group. The result of flow cytometry exhibited apoptotic index in pEGFP-maxizyme group was 22.95%, which was higher than those in blank control group and pEGFP group.
CONCLUSION: The recombinant ribozyme cDNA eukaryotic expression vector pEGFP-maxizyme can be efficiently transfected into MHCC97 cell by adenovirus enhanced transferrin receptor-mediated gene delivery system and the expression of maxizyme may inhibit the mtp53 gene expression and promote apoptosis of MHCC97 cells. The AVET system may be a useful tool in gene delivery for gene therapy of human HCC.
Collapse
|